HbA1c by 0.65% to 1.1% of output from 7.8% to 8.4% of the Lenalidomide Revlimid trials up to 52 weeks was reduced. This improvement to the GLYCOL mix Similar studies embroidered with sulphonylureas or thizolidinediones exenatide when added to metformin. Furthermore, the inhibition of DPP 4 in combination with metformin tion is safe and well tolerated Possible. Therefore, an important indication for treatment with DPP-4 inhibition as an add-on to metformin in patients inadequately controlled Strips metformin and fi rst line in the initial combination with metformin. Future studies should be the lasting effect of the combination of DPP-4 inhibition with metformin be explored detailed mechanistic studies should be conducted, including normal studies on glucagon secretion, lipid and prandial insulin sensitivity.
Type-2 diabetes is increased with a FITTINGS risk kardiovaskul Re diseases where it big one There interest in strategies to kardiovaskul Ren morbidity t and mortality Reduce t associated with diabetes. Despite aggressive treatment of hypertension and Dyslipid Mie reduced kardiovaskul Re events in diabetic and non-diabetic patients time when the blood glucose lowering alone reduces cardiac events in patients with established diabetes remains controversial. In addition, the pharmacotherapy of diabetes with antidiabetic drugs with unique mechanisms with differential and sometimes negative effects on unexpected kardiovaskul Re events are associated, independent Dependent.
Of the effect on glycemic control Therefore seems a detailed amplification Ndnis the unique benefits and kardiovaskul Re risks of each antidiabetic medication used to treat diabetes wise. Both classes of drugs most recently approved for the treatment of type 2 diabetes, GLP-1 receptor agonists and dipeptidyl peptidase-4 exert their antidiabetic largely by potentiating GLP 1R activation. Since these funds were only used clinically for many years, there are few data on kardiovaskul Re events with these incretin-based therapies connected. GLP-1 improves endothelial function in patients with type 2 diabetes and transient GLP-1 administration improved kardiovaskul Re events in patients with acute myocardial infarction or heart failure. Moreover show pr Clinical data, that GLP-1 is cardioprotective if, before the induction of Ish Administered chemistry.
Moreover, the treatment with GLP 1R agonists exenatide and liraglutide is associated with the reduction of the voltage in the plurality of topics. Therefore, although limited, the available data support the hypothesis that antidiabetic therapy may be associated with positive effects on kardiovaskul Re events with GLP-1 can. However, to produce k Can as GLP-1R agonists, weight loss, the extent, Reflecting the positive effects of GLP 1R activation of the cardiovascular system in vivo, the beneficial effects of weight loss remains unclear. In contrast, much less is known about the biology of kardiovaskul Ren DPP 4th Unlike treatment with GLP-1R agonists, the use of sitagliptin, vildagliptin or saxagliptin was not associated with weight loss and sustained improvements in blood lipid levels. Zus Tzlich inhibition of DPP 4 mod enzyme activity T .